Brightgene Bio-Medical Technology Co. Ltd. has patented new calcitonin receptor (CALCR; CT-R) and amylin AMY3 receptor agonists potentially useful for the treatment of obesity and metabolic disorders.
Beijing Avistone Pharmaceuticals Biotechnology Co. Ltd. has reported new GTPase KRAS mutant inhibitors potentially useful for the treatment of cancer, immunological and inflammatory disorders.
The University of Edinburgh has disclosed new benzoxazol mammalian target of rapamycin (mTOR; FRAP1) inhibitors potentially useful for the treatment of cancer, autoimmune, metabolic diseases, fibrosis, parasitic infections, genetic, inflammatory and neurological disorders.
Merck Sharp & Dohme LLC (MSD) has synthesized new benzimidazole derivatives acting as NLRP3 inflammasome inhibitors. As such, they are potentially useful for the treatment of atherosclerosis, metabolic dysfunction-associated steatohepatitis (MASH), neuroinflammation, inflammatory skin, inflammatory joint and autoimmune disease, Alzheimer’s and Parkinson’s disease, among others.
Primo Thera Co. Ltd. has divulged new interleukin-6 receptor subunit β (IL-6Rβ; gp130) inhibitors potentially useful for the treatment of autoimmune disease.
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of psychiatric and neurological disorders.
Recurium IP Holdings LLC has disclosed new Wee1-like protein kinase (Wee1) inhibitors and/or degradation inducers potentially useful for the treatment of cancer.
RSS
